Form 4 for ACAD ACADIA PHARMACEUTICALS INC
Accepted 2023-05-02 00:00:00 ET · period of report 2023-04-29 · accession 0001209191-23-026744 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-05-02 | 2023-04-29 | ACAD | Teehan Brendan | EVP, COO, Head of Commercial | M - OptEx | $0.00 | +1,567 | 10.0K | +19% | $0 |
| D | 2023-05-02 | 2023-05-01 | ACAD | Teehan Brendan | EVP, COO, Head of Commercial | S - Sale+OE | $21.18 | -548 | 9,487 | -5% | -$11.6K |
| D | 2023-05-02 | 2023-04-29 | ACAD | Teehan Brendan | EVP, COO, Head of Commercial | M - OptEx | $0.00 | -1,567 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-04-29 | M | A | 1,567 | $0.00 | 10,035 | D | — | — | |
| 2 | Common | Common Stock | 2023-05-01 | S | D | 548 | $21.18 | 9,487 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2023-04-29 | M | D | 1,567 | $0.00 | 0 | D | — · — to — | 1,567 Common Stock | (F2) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F3) 50% of the shares subject to the restricted stock units vest on each of April 29, 2022 and April 29, 2023. |